#United States #Friendswood #Barrett's Esophagus #Castle Biosciences #TissueCypher

Castle Biosciences' TissueCypher® Test: A Milestone in Patient Care

Castle Biosciences, Inc. has achieved a remarkable milestone, announcing that its TissueCypher® test for Barrett's esophagus has surpassed 100,000 clinical test orders. This innovative test, which utilizes advanced artificial intelligence, aims to predict the risk of progression in patients diagnosed with Barrett's esophagus (BE) to more severe health conditions such as high-grade dysplasia or esophageal adenocarcinoma.

Barrett's esophagus is a significant health concern, being the only known precursor to esophageal adenocarcinoma, a type of gastrointestinal cancer often associated with poor survival rates. According to Dr. Emmanuel Gorospe, a board-certified gastroenterologist and medical director at Castle Biosciences, the TissueCypher test plays a crucial role in risk stratification for BE patients.

With personal stories of patients like Robin Byrd Wilfong, who was motivated to understand her risk after being diagnosed, the test has proven to be invaluable. After her assessment, Robin received a low-risk indication suggesting a mere 2% chance of progression over five years. This knowledge not only relieved her anxiety but empowered her to manage her health proactively.

Advancements in Precision Medicine

The TissueCypher® test stands at the forefront of precision medicine. It is specifically designed for patients with non-dysplastic Barrett's esophagus, indefinite dysplasia, or low-grade dysplasia. The test evaluates an individual’s risk over five years based on molecular signatures that indicate their likelihood of developing high-grade dysplasia or esophageal adenocarcinoma.

Supported by over 17 peer-reviewed publications and research involving more than 8,000 biopsies, this test has been scientifically validated as a superior predictor of cancer progression compared to traditional methods. Its AI-derived spatialomics approach allows clinicians to identify critical molecular changes early, thus enabling timely interventions.

The test integrates smoothly into routine endoscopic practices, analyzing standard esophageal biopsies and providing healthcare professionals with actionable insights without the need for additional procedures. Committed to enhancing patient care, Castle Biosciences emphasizes the importance of informed decision-making in managing Barrett's esophagus.

The Importance of Awareness and Advocacy

In conjunction with its clinical achievements, Castle Biosciences recognizes the vital role of healthcare providers in utilizing technologies like TissueCypher®. Toby Juvenal, the chief commercial officer, expresses gratitude towards the clinicians embracing this tool and the patients advocating for enhanced care approaches.

For patients grappling with a BE diagnosis, gaining clarity regarding their risk can significantly reduce feelings of helplessness. Robin's account highlights this need: "I don't feel like a ticking time bomb. I feel like I've got time to manage this the way I choose." This sentiment echoes the broader goal of Castle Biosciences — to empower both patients and doctors with precise information that enhances the overall quality of care.

As the demand grows for personalized healthcare solutions, the trajectory set forth by TissueCypher demonstrates the shift towards more informed, precise, and proactive patient management strategies.

For more insights on Robin's journey with TissueCypher, you can watch her story on the Castle Biosciences website.

About Castle Biosciences

Castle Biosciences (Nasdaq CSTL) leads the way in diagnostic innovations, developing tests that provide critical insights to aid patient care. With a sharp focus on dermatologic and gastroenterological diseases, they champion personalized, scientifically-sound solutions that enhance patient outcomes. Visit CastleBiosciences.com for further information and to explore their offerings in depth.

Conclusion

Castle Biosciences’ achievement of more than 100k orders for its TissueCypher test signals a significant advancement in the field of gastroenterological diagnostics, promoting patient-centered care through precision medicine. The continued integration of advanced testing in clinical practices is crucial for improving health outcomes in patients facing the challenges presented by Barrett's esophagus.